A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle. The study showed a statistically non-significant benefit in clinical response rates for some patients with early...
Roche released an announcement today in regards to its phase three trial called EMILIA. The program compared performance of its new drug Trastuzumab Emtansine against standard treatments for HER2-positive Metastatic Breast Cancer that use lapatinib plus Xeloda® (capecitabine). Patients were...
The use of trastuzumab, chemotherapy and surgery among women with HER2-positive metastatic breast cancer significantly improved survival from the time central nervous system metastases were diagnosed. Based on these study results, lead researcher Adam Brufsky, M.D., Ph.D., said, "We clearly now...